Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Nov 12 | 2021No Significant Cell Therapy Updates in November’s CHMP Highlights; Celltelligence Reducing Ziopharm’s Coverage; UPDATED: Indications Table for CD19 CAR-T US Approvals and SubmissionsAccess Free Blast
Free
Posted in: Autologous, TCR Nov 12 | 2021Thoughts on Afami-cel’s Promising Clinical and Translational Data for SS and MRCLS; Adaptimmune’s Ph2 SPEARHEAD-1 Trial on Track to Meet Its Primary Endpoint by YE 2021Access Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19, TCR Nov 10 | 2021Precision’s PBCAR20A Deprioritized; TCR2 Tx Focuses on Building up Their Manufacturing Capacity in the US; Precision and TCR2 Tx Q3 2021 Earnings SummariesAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA Nov 10 | 2021Poseida to Prioritize P-BCMA-ALLO1 Over P-BCMA-101; Program Updates for P-PSMA-101 and P-MUC1C-ALLO1; Poseida Q3 2021 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Nov 10 | 2021NICE Suspends Breyanzi’s Appraisal for R/R NHLAccess Free Blast
Free
Posted in: Autologous, TCR Nov 09 | 2021Will Ziopharm Ever be Able to Commercialize Their Cell Therapy Products? Continuing Delays for Ziopharm’s TCR-T Programs; TriArm's Joint Venture Eden BioCell Dissolved; Ziopharm Q3 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, CAR-T Nov 08 | 2021Precision Appoints Sam Wadsworth and Shari Lisa Piré to Their Board of DirectorsAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Nov 08 | 2021Will Yescarta Receive a Positive CHMP Opinion for R/R FL This Week? No Mention of Tecartus or Cilta-cel in November’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19, CD22 Nov 08 | 2021Why Blackstone’s $250M Investment in Autolus Is Necessary for Obe-cel’s Clinical DevelopmentAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD22 Nov 05 | 2021Cellectis Remains Confident on TALEN Editing Safety; UCART22 Clinical Updates Anticipated at ASH 2021; UCARTMESO on Track to Enter the Clinic in 2022; 2seventy Provides Further Insights on Their Business Separation; Cellectis Q3 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Nov 05 | 2021New Yescarta Study in R/R DLBCL for Outpatient AdministrationAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD123, CD19, CD22, CS1 Nov 05 | 2021When Will the FDA Lift Allogene’s Clinical Hold on AlloCAR-T Programs? Allogene to Present Major Clinical Updates at ASH 2021; Could ALLO-501A’s Pivotal Trial Include Consolidation Dosing? Allogene Q3 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, TCR Nov 04 | 2021Afami-cel’s BLA Filing on Track for 2022; Next-Gen MAGE-A4 SPEAR-T To Treat Ovarian Cancer; 2seventy Successfully Launched; Adaptimmune Q3 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19, CD22 Nov 03 | 2021Autolus’s Obe-cel US Regulatory Filing Planned for Early 2023; BMS Invests in Clade Therapeutics; New Gracell CD19 UCAR-T Ph1 Trial in R/R B-ALL and B-NHL Posted; Autolus Q3 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Nov 02 | 2021Thoughts on Cilta-cel US DelayAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Nov 01 | 2021Cilta-cel US Delay to February 28, 2022Access Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Oct 29 | 2021Yescarta’s Sales Decline; Gilead’s (Kite) New Manufacturing Facility in Maryland to Be Operational By Mid-2022; Health Canada Approves Tecartus in MCL; Gilead’s Q3 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Oct 27 | 2021BMS’s Breyanzi and Abecma Sales Increase; Could Abecma’s Continued Viral Vector Shortage Favor Cilta-cel's Upcoming Launch? No Updates on GSK’s Cell Therapy Assets; BMS and GSK Q3 2021 Earnings Call SummariesAccess Free Blast
Free
Posted in: Allogeneic Oct 27 | 2021Takeda to Acquire GammaDelta Tx; Will Gilead (Kite) Pursue Gadeta?Access Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Oct 27 | 2021Novartis Receives Priority Review for Kymriah in R/R FLAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.